BioAmber Inc. (NYSE:BIOA) will release its earnings data before the market opens on Wednesday, November 1st. Analysts expect BioAmber to post earnings of ($0.16) per share for the quarter.

BioAmber (NYSE:BIOA) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.03). BioAmber had a negative return on equity of 56.55% and a negative net margin of 221.82%. The firm had revenue of $4.12 million during the quarter, compared to the consensus estimate of $4.09 million. On average, analysts expect BioAmber to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of BioAmber Inc. (NYSE:BIOA) opened at 0.615 on Wednesday. The company’s market capitalization is $22.82 million. The firm has a 50-day moving average of $0.51 and a 200-day moving average of $1.59. BioAmber Inc. has a 12 month low of $0.32 and a 12 month high of $6.50.

A number of brokerages have recently commented on BIOA. ValuEngine lowered shares of BioAmber from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 8th. Zacks Investment Research upgraded shares of BioAmber from a “sell” rating to a “hold” rating in a research note on Wednesday, July 26th. Finally, Cowen and Company set a $3.00 price target on shares of BioAmber and gave the stock a “hold” rating in a research note on Monday, July 17th.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at

An institutional investor recently raised its position in BioAmber stock. Vanguard Group Inc. lifted its stake in BioAmber Inc. (NYSE:BIOA) by 9.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 303,360 shares of the biotechnology company’s stock after acquiring an additional 27,278 shares during the quarter. Vanguard Group Inc. owned 0.82% of BioAmber worth $780,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 37.40% of the company’s stock.

BioAmber Company Profile

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

Earnings History for BioAmber (NYSE:BIOA)

Receive News & Ratings for BioAmber Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAmber Inc. and related companies with's FREE daily email newsletter.